BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19240166)

  • 21. 15-deoxy-Delta12,14 prostaglandin J2 up-regulates Kruppel-like factor 4 expression independently of peroxisome proliferator-activated receptor gamma by activating the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer cells.
    Chen ZY; Tseng CC
    Mol Pharmacol; 2005 Nov; 68(5):1203-13. PubMed ID: 16077033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4.
    Caja L; Sancho P; Bertran E; Iglesias-Serret D; Gil J; Fabregat I
    Cancer Res; 2009 Oct; 69(19):7595-602. PubMed ID: 19773433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells.
    Zhang D; Putti TC
    Exp Cell Res; 2010 Dec; 316(20):3522-31. PubMed ID: 20833165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
    El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
    Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.
    Ko JC; Tsai MS; Chiu YF; Weng SH; Kuo YH; Lin YW
    J Pharmacol Exp Ther; 2011 Jul; 338(1):184-94. PubMed ID: 21444628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
    J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
    Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
    Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.
    Joyner DE; Albritton KH; Bastar JD; Randall RL
    J Orthop Res; 2006 Mar; 24(3):474-80. PubMed ID: 16450387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2.
    Su ZZ; Lebedeva IV; Sarkar D; Emdad L; Gupta P; Kitada S; Dent P; Reed JC; Fisher PB
    Oncogene; 2006 Apr; 25(16):2339-48. PubMed ID: 16331261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sp1-mediated transcriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal muscle lineage.
    Yu SJ; Zheng L; Ladanyi M; Asa SL; Ezzat S
    Clin Cancer Res; 2004 Oct; 10(19):6750-8. PubMed ID: 15475466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CIAPIN1 confers multidrug resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr cells and is independent of p53.
    Zhang YF; Li XH; Shi YQ; Wu YY; Li N; He Q; Ji Q; Wang RQ; Yang SM; Fang DC
    Oncol Rep; 2011 Apr; 25(4):1091-8. PubMed ID: 21240465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated fibroblast growth factor-inducible 14 expression promotes gastric cancer growth via nuclear factor-κB and is associated with poor patient outcome.
    Kwon OH; Park SJ; Kang TW; Kim M; Kim JH; Noh SM; Song KS; Yoo HS; Wang Y; Pocalyko D; Paik SG; Kim YH; Kim SY; Kim YS
    Cancer Lett; 2012 Jan; 314(1):73-81. PubMed ID: 21993017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1.
    Wang MY; Chen PS; Prakash E; Hsu HC; Huang HY; Lin MT; Chang KJ; Kuo ML
    Cancer Res; 2009 Apr; 69(8):3482-91. PubMed ID: 19351859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression.
    Stadler CR; Knyazev P; Bange J; Ullrich A
    Cell Signal; 2006 Jun; 18(6):783-94. PubMed ID: 16109476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease.
    Chen Q; Jiang Y; An Y; Zhao N; Zhao Y; Yu C
    Biochem Biophys Res Commun; 2011 Jun; 409(4):651-6. PubMed ID: 21616061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disruption of sphingosine 1-phosphate lyase confers resistance to chemotherapy and promotes oncogenesis through Bcl-2/Bcl-xL upregulation.
    Colié S; Van Veldhoven PP; Kedjouar B; Bedia C; Albinet V; Sorli SC; Garcia V; Djavaheri-Mergny M; Bauvy C; Codogno P; Levade T; Andrieu-Abadie N
    Cancer Res; 2009 Dec; 69(24):9346-53. PubMed ID: 19934311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.
    Ye Y; Jiang D; Li J; Wang M; Han C; Zhang X; Zhao C; Wen J; Kan Q
    Tumour Biol; 2016 Mar; 37(3):3185-95. PubMed ID: 26432329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
    Bange J; Prechtl D; Cheburkin Y; Specht K; Harbeck N; Schmitt M; Knyazeva T; Müller S; Gärtner S; Sures I; Wang H; Imyanitov E; Häring HU; Knayzev P; Iacobelli S; Höfler H; Ullrich A
    Cancer Res; 2002 Feb; 62(3):840-7. PubMed ID: 11830541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.
    Turkington RC; Longley DB; Allen WL; Stevenson L; McLaughlin K; Dunne PD; Blayney JK; Salto-Tellez M; Van Schaeybroeck S; Johnston PG
    Cell Death Dis; 2014 Feb; 5(2):e1046. PubMed ID: 24503538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibroblast growth factor receptor 4, implicated in progression of islet cell carcinogenesis by its expression profile, does not contribute functionally.
    Olson DC; Deng C; Hanahan D
    Cell Growth Differ; 1998 Jul; 9(7):557-64. PubMed ID: 9690623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.